Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide | Zendy

Hélio S. Sader | Zendy; Leonard R Duncan | Zendy; S J Ryan Arends | Zendy; Cecília G Carvalhaes | Zendy; Mariana Castanheira | Zendy

Open Access

Antimicrobial Activity of Aztreonam-Avibactam and Comparator Agents When Tested against a Large Collection of Contemporary Stenotrophomonas maltophilia Isolates from Medical Centers Worldwide

Author(s) -

Hélio S. Sader,

Leonard R Duncan,

S J Ryan Arends,

Cecília G Carvalhaes,

Mariana Castanheira

Publication year - 2020

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01433-20

Subject(s) - stenotrophomonas maltophilia , aztreonam , antimicrobial , ceftazidime/avibactam , stenotrophomonas , microbiology and biotechnology , gram negative bacterial infections , antibacterial agent , biology , medicine , antibiotics , pseudomonas aeruginosa , bacteria , antibiotic resistance , pseudomonas , ceftazidime , genetics , imipenem

Aztreonam-avibactam was tested against 1,839 Stenotrophomonas maltophilia isolates collected worldwide and demonstrated potent activity against isolates from all geographic regions and infection types (overall MIC 50/90 , 4/4 mg/liter; 97.8% inhibited at ≤8 mg/liter). Trimethoprim-sulfamethoxazole (TMP-SMX) (MIC 50/90 , ≤0.5/1 mg/liter; 95.4% susceptible) and minocycline (MIC 50/90 , 0.5/2 mg/liter; 99.5% susceptible) were also very active. Aztreonam-avibactam inhibited 84.7% of non-TMP-SMX-susceptible isolates at ≤8 mg/liter. Aztreonam-avibactam may represent a valuable option for the treatment of S. maltophilia infections, addressing a major unmet medical need.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research